trial · primary record
Pembrolizumab
Carcinoma, Non-Small-Cell Lung
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 680 |
| Primary completion | 2038-01-26 |
| Primary endpoint | Disease-Free Survival (DFS) |
| Registry ID | NCT06623422 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-30T14:45:17.169Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06623422
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Pembrolizumab · approval
- Pembrolizumab · compound